Integrating New Data From AIDS 2024: Pharmacist Perspectives

CCO Infectious Disease Podcast

Contenido proporcionado por Clinical Care Options, LLC and Clinical Care Options. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Clinical Care Options, LLC and Clinical Care Options o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

5M ago 18:22

MP3•Episodio en casa

In this episode, Jennifer Cocohoba, PharmD, AAHIVP, and David Koren, PharmD, MPH, AAHIVP, FIDSA, cover the most impactful LA ART and LA PrEP clinical studies presented at AIDS 2024, including:

The PURPOSE 1 study of twice-yearly lenacapavir injections vs daily oral tenofovir as PrEP in cisgender women
An open-label extension of HPTN 084 evaluating LA CAB safety during pregnancy
48-week data from the IMPAACT 2017/MOCHA study of LA CAB + RPV in adolescents with HIV
A substudy of FLAIR evaluating the efficacy, safety, and tolerability of SC self-administration of LA CAB + RPV

Presenters:

Jennifer Cocohoba, PharmD, AAHIVP
Professor of Clinical Pharmacy
Department of Clinical Pharmacy
University of California San Francisco School of Pharmacy
San Francisco, California

David Koren, PharmD, MPH, AAHIVP, FIDSA
Adjunct Clinical Professor
Temple University School of Pharmacy
Clinical Pharmacist Specialist
Temple University Health System
Philadelphia, Pennsylvania
To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. 

See the full program here.

424 episodios

#Science #Fitness #Biology #Higher Education #Podcasting Education #Medicine #Clinical Care Options, LLC #Clinical Care Options #HIV #On Covid19 #CME #Hepatitis B #Hbv #Infectious Disease Medical Education #Id Medical Education #Coronavirus #Hepatitis C #Hcv